Philip Morris
Requested Review of Ohea Document on Passive Smoking Health Risk Assessment
Fields
- Author
- Murphy, P.A.
- Type
- MEMO, MEMORANDUM
- REPT, REPORT, OTHER
- Area
- HAN,VICTOR/SEC'Y FILES
- Attachment
- 2046458056/2046458185
- Recipient (Organization)
- Meds
- Recipient
- Papa, L.
- Request
- Stmn/R1-048
- Site
- N332
- Master ID
- 2046458005/8185
Related Documents:- 2046458005-8010 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Memorandum in Support of Plaintiffs' Motion to Hold in Abeyance Defendants' Motions for Judgement on the Pleadings, to Dismiss Count IV (Due Process) or to Stay Consideration of Count IV Civil Action No. 6:93cv370
- 2046458011-8014 Flue-Cured Tobacco Cooperative Stabilization Corp., Et Al. V. U.S. Environmental Protection Agency, Et Al.
- 2046458015 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Order Civil Action No. 6:93cv370
- 2046458016-8018 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Plaintiffs' Motion to Extend Page Limits Civil Action No. 6:93cv370
- 2046458019 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Order Civil Action No. 6:93cv370
- 2046458020-8052 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Plaintiffs' Memorandum in Opposition to Epa's Motions for Partial Summary Judgement and for A Protective Order Civil Action No. 6:93cv370
- 2046458053-8055 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Order Civil Action No. 6:93cv370
- 2046458056-8058 Flue-Cured Tobacco Cooperative Stabilization Corporation, Plaintiffs, V. United States Environmental Protection Agency, Defendants. Appendix Civil Action No. 6:93cv370
- 2046458059 Avery Algner Legal Index Exhibit Dividers
- 2046458060-8062 Wilfred E. Allick, Jr., Plaintiff, V. Manuel Lujan, Jr., Defendant Allick V. Lujan Opinion: Order Civil Action No. 89-2269 (Crr)
- 2046458063
- 2046458064-8065 Briefing for Dick Morgenstern on Environmental Tobacco Smoke
- 2046458066
- 2046458067-8074 Flue-Cured Tobacco Cooperative Stabilization Corporation Plaintiffs V. United States Environmental Protection Agency Defendants Declaration of Larry R. Glass,Ph.D. Civil Action No. 6:93cv370
- 2046458075
- 2046458076-8090
- 2046458091
- 2046458092 Technical Manuscript Review Form Lung Cancer Hazards and Other Respiratory Effects Due to Exposure to Environmental Tobacco Smoke
- 2046458093 Review of 'lung Cancer Hazards and Other Respiratory Effects Due to Exposure to Environmental Tobacco Smoke'
- 2046458094-8097 Review of the 900400 Internal Draft Document 'lung Cancer Hazards and Other Respiratory Effects Due to Exposure to Environmental Tobacco Smoke'
- 2046458098-8101 Review of Ets Report
- 2046458102
- 2046458103-8105 Ohea-C-361 - Respiratory Health Effects of Passive Smoking Lung Cancer and Other Disorders
- 2046458106 Technical Manuscript Review Form Respiratory Health Effects of Passive Smoking: Lung Cancer and Other Disorders
- 2046458107-8109 Ohea-C-361 - Respiratory Health Effects of Passive Smoking Lung Cancer and Other Disorders
- 2046458116-8118 Review of the Report on Respiratory Effects From Ets
- 2046458119-8138 Health Effects of Passive Smoking: Assessment of Lung Cancer in Adults and Respiratory Disorders in Children
- 2046458139
- 2046458140-8158 Review of the U.S. Environmental Protection Agency's Tobacco and Smoke Study Hearing Before the Subcommittee on Specialty Crops and Natural Resources of the Committee on Agriculture House of Representatives
- 2046458159 5
- 2046458160-8162 Antonio Cipollone, Plaintiff, V. Liggett Group, Inc., Defendant - Appellees, and Otis R. Bowen, Appellant, V. Liggett Group, Inc., Defendant - Appellees. Nos. 86-1198, 86-1223. United States Court of Appeals, Fourth Circuit. Argued 861211. Decided 870213.
- 2046458163 6
- 2046458164-8180 Statement of Dr. Jane G. Gravelle Senior Specialist in Economic Policy and Dr. Zimmerman Specialist in Public Finance Congressional Research Service Before the Subcommittee on Clean Air and Nuclear Regulation Committee on Environment and Public Works United States Senate 940511 on Environmental Tobacco Smoke
- 2046458181 7
- 2046458182 Air Quality Bad News on Second-Hand Smoke
- 2046458183 8
- 2046458184-8185 Epa Panel Reports Non-Smokers at Risk
- Named Organization
- Ecao Cin
- Epa, Environmental Protection Agency
- Author (Organization)
- Epa, Environmental Protection Agency
- Meds
- Named Person
- Sandler
- Greenland, S.
- Hertzberg, R.
- Leaderer, B.
- Maclure, M.
- Greenland, S.
- Litigation
- Stmn/Produced
- Date Loaded
- 05 Jun 1998
- UCSF Legacy ID
- xua65e00
Document Images
UNiTED STATES ENVIRONMENTAL PROTECTION AGENCY
OFFICE OF RESEARCH AND DEVELOPMENT
ENVIRONMENTAL CRITERIA AND ASSESSMENT OFFICE
CINCINNATI, OHIO 45268
March 23, 1992
SUBJECT: Requested review of OHEA document on Passive Smoking
Health Risk Assessment
FROM: Patricia /~!~~~`p
MED ~'' , id iologist
S
TO: Lynn Papa
Acting Chief
MEDS
Although we were asked to review specific portions of this
document, it is our collective opinion that this is a
scientifically inadvisable means of approaching the issue. We
found that we were repeatedly forced to either accept certain
statements and assumptions at face value or go back in the previous
chapters to seek out the information needed for a thorough
assessment of the validity of some the analytical approaches which
were taken. Our Office has had no involvement in the development
of this important document and as such we are not aware of the
rationale for selecting the chosen means of data analysis and
presentation, nor are we aware of any scientific deliberations that
have taken place in relation to previous reviews of this document.
It is our belief that if a document was not written in such a
way that each chapter can stand on its own, then it cannot and
should not be reviewed in that way. If the calculations which are
used to generate estimates of risk are well known and straight
forward then it is easier to review them for accuracy, clarity,
and appropriateness of application. If, however, commonly used
formulae have been adjusted or manipulated in any way, it becomes
impossible to evaluate their validity if they are presented without
supporting documentation and references for the various assumptions
implicit in their use.
ECAO-CIN was asked to provide statistical reviews of Chapters
6 & 8 and Appendix B, and to provide epidemiologic reviews of
Chapter 5 and Appendix A. It was evidently not recognized that
most of Chapter 5 revolves around the statistical summarization and
pooling of the results of approximately 30 epidemiologic studies of
varying design and quality (often referred to as "statistical meta-
analysis"). The severe time constraints of this requested review
did not allow either Rick Hertzberg or me to review all these
sections in a comprehensive manner. Rick's comments on Chapter 8
1
~ Printed on Recycled Paper

and Appendix B are included as an attachment to my comments here.
I also briefly looked through Chapter 8 and Appendix B and concur
with Rick's comments. In addition, we noted an error in Table B-
15: Col. labelled "former smokers", line 2 now reads 38%. This
should be 21%.
The primary focus of my comments is on Chapter 5. I also had
to spend time reading through Chapters 1, 2, and 3 in order to
familiarize myself with the document's overall thrust and to assess
the validity of some of measurements which are used to assess
exposure to passive smoking. I have made a lot of comments in the
document itself, not all of which will be summarized here, so the
authors' should look at the sections which are being returned for
a full commentary. As mentioned above, the time constraints of the
allowed review time necessitate a less thorough commentary than
would otherwise be warranted. In many instances, I have raised a
lot of questions but have not been able to fully evaluate the
potential impact of some of my concerns regarding data
presentation, analysis and interpretation. I have tried to make my
comments as constructive as possible, although brevity may make
many of them seem quite terse. I will now address the major
concerns I have regarding the Chapters I was able 'to read and
assess.
Chapters 1 & 2: see minimal comments noted on document.
Chapter 3:
1. It is never really stated as to whether there is any
concordance regarding levels of cotinine in blood, urine, and
saliva although in some cases these different measurements are
compared across studies. These measurements are used as the basis
of several assumptions for the adjustment of some of the summary
statistics presented and a more complete discussion of the
sensitivity and specificity of the measures should be included as
a justification for their use.
2. In several places, references are listed numerically, which is
inconsistent with the rest of the document (see chapter for
specifics).
3. Some parts of this chapter bear a rather striking resemblance
to an article by Brian Leaderer (1990). Risk Analysis, Vol. 10
pp. 19-26. In same cases, the wording is identical. It may be
that this person also authored this chapter. If not, this could be
a source of embarrassment as there are surely many people familiar
with this article who will also be reading this EPA document in
some capacity. This should be looked into by the authors.
Chapter 4: Did not read, only looked at some of the tables for
general information. No specific comments.
2

Appendix A: Reviews of Epidemiologic Studies on ETS and Lung
Cancer.
This appendix reviewed 32 epidemiologic studies and was 163
pages long. As such, I could not review it in any detail on a
study by study basis; I also did not have the original studies to
refer to if so necessary. I do have several specific
recommendations to improve this section. Right now, the
introduction does not really say too much of interest. What is
lacking is a clear statement of why these particular studies were
selected for review. Was any attempt made to include non-published
studies (which are likely to have non-positive findings) in the
review? Chapter 5 uses these studies as the basis of a meta-
analysis, but it is not really clear to me how the process of data
abstraction took place, i.e., the specific pieces of information
which were being sought from each study to form the data set for
reanalysis. This could be presented in tabular form at the end of
each studies' review and would be a very useful information source.
It would also be helpful to present some type of summary of the
histological classification of the lung cancers included in these
studies stratified by smoking and ETS classification whenever
possible. I tried to reconstruct this information for a couple of
the studies but was unable to with the information presented. I do
recognize that this information was not always adequately presented
in the original references.
Chapter 5:
1. This might be better titled REinterpretation of studies based
on REanalysis of published data. Meta-analysis is repeatedly
alluded to but it is never clearly stated what the purpose and form
of this data reanalysis really is. For example, Sander Greenland
has authored a magnificent explication of meta-analysis and meta-
analytic techniques for specific application to epidemiology but
this is not referenced anywhere (Greenland, S. (1987).
Quantitative Methods in the Review of Epidemiologic Literature.
Epidemiologic Reviews 9: 1-30.) In fact there is no reference
other than the "methods of Mantel & Haenszel" provided for any of
the statistical methods employed in this chapter. It is unclear
what the objective of the analysis is because it is never stated.
2. An introductory section must be included which fully explains
the purpose of this chapter, the data to be used, the statistical
methods employed and ALL the assumptions and limitations inherent
in their use. As presented, it appears that pooling of summary
data (which have been adjusted with extraneous data) across
epidemiologic studies is a daily exercise for most people. I do
not think that this is the case. I recommend following the
procedure outlined by Greenland to be sure that all necessary items
have been included. For example, there is no discussion or mention
of the "file drawer problem", i.e., existence ofunpublished
studies showing no positive effects, which may bias the results of
3

trie data pooling in the direction of finding a positive effect.
3. I suggest that formulae be given in explicit terms for all the
summary statistics presented. For example, right now we only know
the relative weight of each study included but do not know it true
weight (inverse variance). There is also no mention of the
potential effect on the variance (albeit it likely small) when
using an odds ratio that has been extraneously adjusted but the
variance formula for the (apparently) crude measure. It would be
helpful to summarize some of these statistics in.a more complete
manner (see tables 1 & 2 in Greenland) so that they can be used by
a reviewer/reader of this document to look at the data in other
ways than those presented.
4. No where could I find a thorough discussion of the validity of
the summary odds ratios, particularly regarding the assumption of
homogeneity of the effect measure across studies. It is alluded to
indirectly but never stated. This is a crucial assumption in data
pooling and should be explicitly discussed.
5. It seems that several studies were excluded a priori from the
meta-analysis for evidently different reasons. It is mentioned
that the study of Sandier et al. was excluded to a small number of
lung cancer cases--I thought. the purpose of pooling data was to
include studies such as these. If it was totally useless, this
should be more clearly stated.
6. I feel that the entire section on Statistical Inference (5.3)
lacks clarity and assumes too much is known by the reader. This
document will be read by a wide variety of people with different
backgrounds and could become very confusing very quickly as
presented. For example: a) the discussion of power issues is
inadequate and there is no reference given for method of
calculation. It should probably be explicitly stated that
"power = 1-(beta-error)" as the text discusses and presents beta-
error, but the Tables present power; b) in the section Tests for
Association (5.3.2.1) there is suddenly a reference to
standardized odds ratios but we are never told how these were
calculated--I feel the data should be presented in a manner which
is amenable to reanalysis by another party; Figures 5-1 through 5-4
which accompany this section are unclear to me--there is no label
on the x-axis for the log(OR) values but they are referred to in
the text. It is also not clear whether the line on the graphs
really represent the five equal areas under the normal curve which
again are referred to in the text. How were confidence intervals
calculated in section 5.3.2.2?; in Tests for Trend (5.3.2.3) I feel
the importance of the trend test and its associated p-value is
overstated--misclassification and measurement error can mask a
dose-response trend but it can also sometimes create one. In some
cases, there is a significant p-value but examination of the data
shows that there is not a consistent upward trend in the odds
ratios (See M. Maclure and S. Greenland (1992). Tests for trend
4

and dose-response: misinterpretations and alternatives. Am J
Epidemiol 135: 96-104.). Also, it is not clear whether the p-
values for trend tests are one-sided or two-sided and whether they
all represent the authors' original calculations or are
recalculations for this document--were any of these estimates
adjusted for misclassification of smoking status?
See the text for any further comments on these issues.
7. For section 5.4, the passages quoted from the Breslow and Day
textbooks should be properly cited with specific page references.
The discussion of bias and confounding in the individual studies is
pretty thorough, but there is no mention of the potential for
residual confounding in or misclassification of erroneously
measured variables used for the purpose of confounding adjustment.
It is known (see Greenland, 1987 for citations) that this type of
error can result in a variety of types and directions of
misclassification bias of unknown magnitude. This might seem a to
be an overly picky comment, but I believe it should be discussed
because I'm sure some outside critic will cite this source of
potential error as possibly accounting for the positive findings in
these studies.
8. In the last part of Chapter 5, I feel that the case for a clear
causal relationship between lung cancer and ETS is somewhat
overstated. Specifically, there is what seems to be a
misinterpretation of the criterion "specificity". The only studies
which were looked at in this review involved lung cancer so this is
not "specific" to the ETS issue. Specificity would involve, e.g.,
the finding of the same histologic type of lung cancer in all the
studies. It is alluded to that adenocarcinoma seems to be most
strongly related to ETS exposure--is it not curious that among
active smokers squamous cell carcinoma is usually found in
abundance and the relative risks for adenocarcinoma among active
smokers are dwarfed in comparison with those for squamous cell?
This has not been thoroughly discussed and I feel it detracts from
the presumed causal relationship of lung cancer and ETS. I recall
7 or 8 years ago when it was first noted that adenocarcinoma seemed
to occur with greater frequency in women compared to men. At that
time, the theory was that these adenocarcinomas were likely due to
domestic radon exposure; now they are being attributed to ETS.
This issue should be better addressed before a causal relationship
is "confirmed".
Chapter 6: I did not get to read this in any detail. I did wonder
why no calculations were made for the individual studies regarding
attributable fraction (AF) estimates using the calculated odds
ratios. A true confidence interval could have been calculated for
AF and they could have been compared across studies in this way.
Just another way of looking at this data, I guess.
5

Chapter 7: I did not look it at all.
REFERENCES: Many of the references mentioned in the text are not
included here. If the references are not up-to-date, this should
be stated up front to reviewers to save them the time of searching
for things which do not exist. I did note many typographical
errors which I marked as such in the document.
Appendix C: Looked over, no review required (Summary Form to aid
in classifying epidemiologic studies).
Appendix D: Incomplete as received. Sections D.2 and D.3. are
missing, which make it impossible to review the methods for
calculation of the attributable risk estimates which form the basis
of Chapter 6. It should be noted that the concepts of attributable
risk (both population and among the exposed) and attributable
fraction are never formally defined nor their calculation and
limitations formally discussed nor properly referenced (see Rick's
comments). This must be done somewhere.
This concludes my comments on this document. I hope that they will
help to improve the quality of the final product.
6
